Verona Pharma loses Chief Medical Officer

pharmafile | April 11, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, pharma, verona pharma 

Verona Pharma has revealed that it is to part ways with its Chief Medical Officer at the end of the month. Dr Kenneth Newman will leave the company effective 30 April to “pursue other opportunities”, it was announced.

Newman joined the company in the role in January 2015, having previously served at Australian regenerative medicine firm Mesoblast as Chief Development Officer since December 2013. Prior to this, he held the position of Chief Medical Officer at Acton Pharmaceuticals from 2010.

Jan-Anders Karlsson, CEO of Verona Pharma, commented: “We thank Ken for his outstanding service and many contributions to the Company. Over the past three years, he has led the acceleration of RPL554’s clinical development program into Phase 2b trials and overseen seven successful clinical trials. He played an instrumental role in establishing our US presence and we wish him the best in his future endeavours.”

A successor to the role has not yet been named. Verona announced alongside Newman’s departure that it had launched an executive search in order to find a replacement.

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


Verona Pharma submits FDA New Drug Application for COPD treatment

UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to …

Latest content